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Abstract 
Purpose 
The feasibility of preparing an eslicarbazepine acetate suspension using Aptiom® tablets for 
administration via enteral feeding tubes was evaluated.   
Methods 
Eslicarbazepine acetate suspension (40 mg/mL) was prepared using Aptiom® tablets after 
optimizing the tablet crushing methods and the vehicle composition. A stability-indicating HPLC 
method was developed to monitor the eslicarbazepine stability in the prepared suspension. Three 
enteric feeding tubes of various composition and dimensions were evaluated for the delivery of 
the suspensions. The suspension was evaluated for the physical and chemical stability for 48 
hours.    
Results 
The reproducibility and consistency of particle size reduction was found to be best with standard 
mortar/pestle. The viscosity analysis and physical stability studies showed that ORA-Plus®: 
water (50:50v/v) was optimal for suspending ability and flowability of suspension through the 
tubes. The developed HPLC method was found to be stability-indicating, and suitable for the 
assay of eslicarbazepine acetate in the prepared suspension.  
The eslicarbazepine concentrations in separately prepared suspensions were within 
acceptable range (± 3%), indicating accuracy and reproducibility of the procedure. The 
eslicarbazepine concentrations in suspensions before and after delivery through the enteric 
feeding tubes were within acceptable range (± 4%), indicating absence of any physical/chemical 
interactions of eslicarbazepine with the tubes, and a successful delivery of eslicarbazepine 
dosage via enteric feeding tubes. The stability study results showed that eslicarbazepine 
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concentration in the suspension remained unchanged when stored at room temperature for 48 
hours.  
Conclusion 
The study presents a convenient procedure for the preparation of a stable suspension of 
eslicarbazepine acetate (40 mg/mL) using Aptiom® tablets, for administration via enteral feeding 
tubes.  
 
 
 
 
 
 
 
 
 
 
Index terms (keywords) 
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1. Introduction 
Aptiom® (eslicarbazepine acetate) is an anticonvulsant drug indicated for an adjunctive treatment 
of partial-onset seizures.1 It is a part of the antiepileptic class of medications commonly used in 
intensive care patients to prevent seizures.1 Currently Aptiom® is available as 200 mg, 400 mg, 
600 mg, and 800 mg immediate-release tablets. These tablets are recommended to be 
administered orally, may be crushed, and taken with/without food.  
In an intensive care setting, there are a growing number of patients who receive food and 
nutrition via enteral feeding tubes.2-4 Administration of medication through enteral feeding tubes 
offers several advantages over the parenteral route.5 The common benefits include economy, 
convenience, compliance, and most importantly lower probability of infections. However, along 
with the benefits, medication administration through enteric feeding tubes is associated with 
several challenges.6 First, commercially available oral solid drug products, such as Aptiom® 
tablets, cannot be administered directly via enteral feeding tubes. They need to be formulated 
into an appropriate liquid form by extemporaneous compounding, which is typically carried out 
by a pharmacist. Secondly, a variety of feeding tubes with different diameters, openings, lengths, 
and polymer compositions are employed in a hospital setting, thus adding to the complexity of 
drug administration. Furthermore, several studies have reported varying degrees of drug loss 
when administered via enteric feeding tubes.7-15  Clark-Schmidt et al. studied the delivery of 
carbamazepine (an antiepileptic drug) suspension via polyvinyl chloride (PVC) nasogastric 
tubes.16 The authors reported losses (ranging 2-23.6 %) of carbamazepine in an undiluted 
suspension due to physical interaction (adhesion) with the PVC nasogastric (NG) tubes. Thus, 
preparing a compounded liquid formulation from a commercially available oral solid drug 
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product requires a careful formulation strategy and a thorough evaluation of factors that may 
influence the delivery of drugs via enteric feeding tubes.  
Currently, there are no reports in the literature describing the administration of an 
extemporaneously compounded suspension of eslicarbazepine acetate via enteric feeding tubes. 
The presented study was aimed at exploring the feasibility of delivering an extemporaneously 
compounded suspension of eslicarbazepine acetate, prepared using Aptiom® tablets, via enteral 
feeding tubes. The accuracy and short-term chemical stability of eslicarbazepine acetate in the 
prepared suspension was assessed to optimize the compounding/administration procedures for 
health care providers. 
2. Materials 
Eslicarbazepine acetate powder (pure) and Aptiom® tablets (200 mg, 400 mg, 600 mg, and 800 
mg) were obtained from Sunovion Pharmaceuticals, Inc., Marlborough, MA. ORA-Plus® was 
obtained from Perrigo, Minneapolis, MN. Bard® NG tube, polyvinyl chloride (PVC, 18 Fr. 
diameter, 48 length) and Bard® NG tube, polyvinyl chloride (PVC, 10 Fr. diameter, 36 length) 
were obtained from C.R. Bard, Inc., Covington, GA. Kangaroo NG tube (polyurethane, 10 Fr. 
diameter, 36 length) was obtained from Covidien, Mansfield, MA. All other chemicals used in the 
study were of analytical grade. 
3. Methods 
3.1. Preparation of suspension from Aptiom® tablets (choice of tablet crushing method 
and suspending medium) 
The eslicarbazepine acetate suspensions from Aptiom® tablets were prepared, in general, by 
crushing the tablets and suspending the obtained powder in a predetermined volume of the 
suspending vehicle. In order to ensure consistency and convenience in preparing suspensions, 
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commonly used tablet crushing methods, viz. standard mortar-pestle, Pillcrusher Medication 
Delivery Syringe, and Silent Knight® pill crusher were evaluated for the ease-of-use, efficiency, 
and consistency of particle size reduction. The tablets were crushed using each of these methods, 
and the resulting powder was subjected to particle size analysis using laser scattering particle 
size analyzer (Model: Partica LA950-A2, Horiba Instruments, Inc., Irvine, CA). All experiments 
were performed in triplicate. 
 The choice and optimization of the vehicle for preparing suspensions of Aptiom® tablets 
was based on a balance of potential suspending ability and flowability through the enteric 
feeding tubes. Binary mixtures of ORA-Plus® (a commercially available suspending vehicle) and 
water, in different ratios, were evaluated for viscosity to assess the suitability for preparing 
eslicarbazepine acetate suspensions. To further confirm the suitability of suspension preparation, 
several eslicarbazepine acetate suspensions (40 mg/mL) were prepared using different ratios of 
ORA-Plus®: water as a vehicle. These suspensions were analyzed for physical stability and 
viscosity (Model: DV2T Viscometer, Brookfield engineering, Inc., Middleboro, MA) to optimize the 
choice of vehicle. 
 For analysis, an aliquot (1.25 mL) was withdrawn from each suspension sample and 
diluted with a methanol: purified water (50:50 v/v) solution in a 50 mL volumetric flask. The 
samples were then sonicated for 10 minutes. Using a 3 mL plastic syringe, a sample of each 
dilution was filtered through a 0.45 μm nylon syringe filter. 
3.2. High Performance Liquid Chromatography (HPLC) Assay 
A high performance liquid chromatography (HPLC) method was developed to analyze the 
eslicarbazepine concentration in the prepared Aptiom® suspensions. The analysis was performed 
using a HPLC system (model: LC-2010AHT, Shimadzu Scientific Instruments, Marlborough, 
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MA) equipped with a C18 column (Phenomenex Luna, 150 x 4.6 mm, 3 µ, 100 A). The mobile 
phase consisted of methanol and water (50:50 v/v) with 0.1% trifluoroacetic acid. The mobile 
phase flow rate was maintained 0.8 mL/min for a total 15 minute run time, and the column oven 
temperature was maintained at 40°C. The sample injection volume was 3 µL, and the detection 
wavelength was set at 230 nm. Under these conditions the retention time of eslicarbazepine was 
observed to be about 8.7 minutes.  
For calibration purpose, standards of 0.8, 0.9, 1.0, 1.1, and 1.2 mg/mL eslicarbazepine were 
prepared from pure drug powder in methanol: water (50:50 v/v). This range encompasses 80-
120% of the nominal concentration of the study samples. A calibration curve was constructed on 
each day of analysis by plotting the peak area of eslicarbazepine against concentration. The 
curves were found to be linear over the concentration range of the standards with R2 = 0.99 or 
better. Each standard was injected three times to verify method precision. The intraday and 
interday coefficients of variation were within 1 %. 
3.3. Forced degradation studies 
A forced degradation study was conducted to verify the ability of the HPLC method to separate 
the potential degradation products from the parent drug. Four samples of 0.1 mg/mL 
eslicarbazepine solution in methanol: water (50:50 v/v) were prepared, and exposed to extreme 
pH and oxidative stress conditions as shown in Table 1. 
3.4. Evaluation of tube delivery 
Three enteric feeding tubes i.e., PVC/18 Fr/48", PVC/10 Fr/36", and Polyurethane/10 Fr/36" 
were evaluated for the delivery of the prepared eslicarbazepine acetate suspensions. 
Eslicarbazepine acetate suspensions were prepared using the above method at 40mg/mL.  
Feeding tubes were mounted to a board to mimic the position the tube would be in a patient.  An 
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oral syringe was attached to the top of the feeding tube, the suspension (30 mL) was allowed to 
flow through the tube via gravity, and the samples were collected after passing through the tube 
for evaluation. Each tube type was tested three times using a clean/new tube each time (n=3). 
Three dilutions were prepared from each sample using the method described above. Dilutions 
were evaluated using the developed HPLC method and samples were injected in triplicate for 
each dilution. Peak area for each sample was compared to a calibration curve developed each 
day. 
3.5. Stability of eslicarbazepine acetate suspension 
The chemical stability assessment of the optimized suspension was performed at time zero 
(immediately after preparation), at 24 h, and at 48 h after preparation. Samples were stored in 2 
Oz liquid dispensing vials at room temperature, and the suspensions were inspected visually for 
uniformity at each time point. Each sample was analyzed by a stability indicating HPLC method 
described above. Three injections were performed for each of the samples. 
4. Results and discussion 
4.1. Preparation of eslicarbazepine acetate suspension 
The results of particle size analysis of the powders obtained by crushing the tablets using (A) 
Pillcrusher Medication Delivery Syringe, (B) Silent Knight® pill crusher, and (C) standard 
mortar/pestle are shown in Figure 1 and Table 2. In general, powders obtained after crushing the 
tablets by either Pillcrusher syringe or the Silent Knight® pill crusher exhibited larger mean 
particle size (~400 μm). The statistical standard deviation (indicating consistency between 
replicates) was also found to be higher by these methods. Tablet components formed a thick 
layer on the inner surface of the syringe. Crushing the tablets using standard mortar/pestle 
appeared to produce powders with significantly lower mean particle size (~70 μm). The 
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reproducibility and consistency of particle size reduction was also found to be significantly better 
(Std. Dev. ~2.5 μm). Lower particle size is important to formulate a physically stable suspension 
and avoid rapid sedimentation of particles. Moreover, considering the fact that the suspensions 
were prepared with an intent to be delivered via enteral feeding tubes (most with narrow lumen 
diameter), achieving lowest possible particle size was critical. Based on the above observations, 
standard mortar/pestle was selected as a preferred method for crushing Aptiom® tablets to 
prepare the suspensions. 
 Binary mixtures of ORA-Plus® and water, in different ratios, were evaluated for viscosity 
to assess the suitability for preparing eslicarbazepine acetate suspensions. Figure 2 shows the 
viscosity profiles of these binary mixtures as a function of spindle cone speed (shear rate). In 
general, the viscosity of the mixtures decreased with increasing rate of shear. This is known as 
‘shear-thinning’ and is a well-known phenomenon observed with most non-Newtonian liquids. 
For a given shear rate, the viscosity of the binary mixture decreased in a near-linear manner with 
increasing ratio of water. This was also expected considering the differences in the native 
viscosities of ORA-Plus® and water. Preliminary experimental trials showed us that liquids with 
viscosities of 1000 cPs or below demonstrated acceptable flow through the enteric tubes. Thus, 
ORA-Plus®: water ratios of 50:50 v/v, or lower were initially considered for the preparation of 
eslicarbazepine acetate suspensions. 
 The HPLC results confirmed that 40-60 mg/mL suspensions could be prepared accurately 
and reproducibly. Two suspensions (40 mg/mL or 60 mg/mL) were prepared using ORA-Plus®: 
water (50:50 v/v) as a suspending vehicle, and evaluated for viscosity. The results were 
compared with the viscosity profile of ORA-Plus®: water (50:50 v/v) (Figure 3). In general, the 
viscosity of the prepared suspensions were found to be higher compared to the vehicle, 
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significantly at the low shear rates. At any given shear rate, suspension containing 60 mg/mL 
eslicarbazepine exhibited higher viscosity compared to that containing 40 mg/mL 
eslicarbazepine. Based on the viscosity profiles, the drug concentration of 40 mg/mL was 
selected for suspension development and analysis. To further confirm the suitability of 
suspension preparation, several suspensions (40 mg/mL) were prepared using different ratios of 
ORA-Plus®: water as a vehicle. These suspensions were analyzed for physical stability and 
viscosity to optimize the choice of vehicle. Figure 4 shows the viscosity profiles of these 
suspensions as a function of spindle cone speed (shear rate). As observed with blank vehicles 
(ORA-Plus®: water binary mixtures), the viscosity of the mixtures decreased with increasing rate 
of shear. For a given shear rate, the viscosity of the suspensions decreased in a near-linear 
manner with increasing ratio of water. Based on these observations, eslicarbazepine acetate 
suspension (40 mg/mL) prepared using ORA-Plus®: water ratio of 50:50 v/v was found to be 
optimal for delivery through the enteric tubes. 
 The physical stability of the prepared suspensions was assessed by storing the 
suspensions in glass vials, and visually observing the settling behavior (particle sedimentation) at 
0, 2, 4, 24, and 48 hours. As shown in Figure 5, suspensions prepared with vehicles containing 
50% or more ORA-Plus® were observed to be physically stable at the end of 48 hours. No 
settling behavior was observed in these suspensions. For suspensions prepared with vehicles 
containing more than 50% water, the extent of particle sedimentation was in proportion to the 
amount of water. For instance, suspension prepared with ORA-Plus®: water ratio of 30:70 v/v 
exhibited complete settling with separate solid and liquid phases distinctly visible. Thus, based 
on the viscosity and physical stability observations, eslicarbazepine acetate suspension (40 
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mg/mL) prepared using ORA-Plus®: water ratio of 50:50 v/v was found to be optimal for 
delivery through the enteric tubes.  
4.2. Forced-degradation studies 
Extreme pH and oxidative stress conditions were used to challenge eslicarbazepine solutions (0.1 
mg/mL) in methanol: water (50:50 v/v) in order to assess the suitability of the developed HPLC 
method for the analysis of eslicarbazepine acetate suspensions (Table 1). The degradation of 
eslicarbazepine occurred rapidly at extreme pH conditions. The sample challenged with extreme 
acidic condition (1N HCL, pH-2) showed a 49% loss of eslicarbazepine at the end of 48. The 
sample challenged with extreme alkaline condition (1N NaOH, pH-12) exhibited a complete loss 
of eslicarbazepine within 15 min. The degradation products were well separated from the parent 
drug, and no interference of the parent drug peak with those of the degradation products was 
observed. Eslicarbazepine was observed to be relatively stable under the two oxidative stress 
conditions. For sample spiked with hydrogen peroxide (3%) and incubated at 60°C, 
approximately 8% drug loss was observed at the end of 5 days. For sample spiked with hydrogen 
peroxide (3%) and exposed to direct sunlight (ambient room temperature) approximately 1.5% 
loss of eslicarbazepine was observed. Similar to samples treated with extreme pH conditions, 
these samples also exhibited a good separation of degradation products, without interference of 
the parent drug peak with those of the degradation products. Therefore, the developed HPLC 
method was considered stability-indicating, and suitable for the proposed stability and enteric 
tubes delivery study of eslicarbazepine acetate suspension. 
4.3. Delivery of optimized eslicarbazepine acetate suspension via enteric tubes 
In order to ensure the accuracy and consistency of compounding procedure, two sets of three 
eslicarbazepine acetate suspensions were separately prepared and analyzed for eslicarbazepine 
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content using the developed HPLC method. The results are shown in Table 3. The mean 
concentration of eslicarbazepine in the prepared suspensions from trial 1 and trial 2 were found 
to be 98 % and 101% of the nominal concentration, respectively. These results confirmed that 
the suspension compounding procedure consistently yielded the expected concentration of drug, 
and could be used for tube evaluation. 
 The prepared eslicarbazepine acetate suspension deliverability and compatibility with 
enteric feeding tubes, as indicated by eslicarbazepine concentration in the suspensions collected 
after passing through the tubes, is presented in Table 4. After the suspension traversed the tubes 
completely, the tubes were visually inspected for the presence of any residual fluid.  While some 
residual volume was observed in each of the three tube types, none of the tubes exhibited any 
signs of blockage. With a 30 mL suspension volume introduced, the volume collected after the 
suspensions passed through the tube averaged 26 mL. The passage of the suspensions through 
the tubes was assisted by gravity, and took less than 4 min for complete delivery. The results 
showed that there was no reduction of eslicarbazepine concentration with any of the feeding tube 
types tested. The results demonstrated slightly higher drug concentrations in the collected 
suspensions after passing through enteric tubes. These observations are expected and can be 
attributed to pipetting accuracy in preparing dilutions. The concentrations were acceptable based 
on the potency range of the source products. The concentration of eslicarbazepine in suspension 
after passing through the tubes was acceptable for all tube types. These observations also 
indicated the absence of any physical or chemical interaction of the drug with the enteric tubes. 
To ensure a complete delivery of drug dosage, a water flush could be used to rinse the residual 
volume of suspension through the tube. After medication administration, tubes are typically 
flushed with 15-30 mL of water.4  
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4.4. Stability of optimized eslicarbazepine acetate suspension 
The prepared eslicarbazepine acetate suspension was subjected to a 48 hour stability study at 
room temperature. The suspensions were analyzed for eslicarbazepine concentrations at time 0 
(initial concentration), at 24 hours, and at 48 hours. As shown in Table 5, the mean 
eslicarbazepine concentrations in the prepared suspensions ranged between 101% and 104%. The 
storage did not appear to have an influence on the chemical stability of the suspensions. Visual 
inspection revealed that the suspension remained uniform for the duration of storage, with no 
observed settling behavior. While carbamazepine has been reported to adhere to certain types of 
delivery tubes, these results indicate that eslicarbazepine suspension (eslicarbazepine acetate 
suspension, 40 mg/mL) prepared using ORA-Plus®: water (50:50 v/v) as suspending vehicle, 
does not interact physically or chemically to the plastic tubing, thus making it suitable for 
delivery though PVC/18 Fr/48", PVC/10 Fr/36", and Polyurethane/10 Fr/36" tubes.16 A general 
guideline procedure to be used by the healthcare professionals for the preparation of a stable 
eslicarbazepine acetate suspension using Aptiom® tablets is shown in Appendix 1. 
5. Conclusions 
A 40 mg/mL suspension of eslicarbazepine acetate in ORA-Plus®: water (50:50 v/v) was 
identified as suitable for administration through enteral feeding tubes. The concentration of 
eslicarbazepine after passing through the selected enteric feeding tubes was found to be within 
acceptable range (± 10%) of the label claim. The eslicarbazepine acetate suspension in ORA-
Plus®: water (50:50 v/v) was found to be the easiest to prepare, and stable at room temperature 
for 48 hours without compromising the integrity of the suspension. The study presents the 
feasibility of preparing an extemporaneous suspension of eslicarbazepine for delivery via enteric 
feeding tubes, using Aptiom® tablets.  
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Appendix 1 
General guideline procedure for the preparation of a stable eslicarbazepine acetate suspension 
using Aptiom® tablets: 
a) Prepare 30 mL suspending vehicle i.e., ORA-Plus® and purified water (50:50 v/v). 
b) Crush the desired dose (1200 mg) of Aptiom® tablets in a mortar and pestle.  
c) Add 10 mL of vehicle i.e., ORA-Plus®: water (50:50 v/v) to a mortar and triturate until 
there are no visible clumps.  
d) Pour the mixture into a dispensing container/vial. 
e) Rinse the mortar and pestle with a small amount of vehicle (5-10 mL) and add to the 
dispensing container/vial. 
f) Make up the volume of the suspension in the dispensing cup by adding the remaining 
quantity of the vehicle.  
g) To administer, pour suspension into oral syringe attached to top of feeding tube and allow 
it to flow through via gravity.  
h) After administration of the suspension, flush the tubing with 15-30 mL purified water.  
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Figure captions 
Figure 1: Particle size analysis of the powder obtained after crushing the tablets using (A) 
Pillcrusher Syringe, (B) Silent Knight® pill crusher, and (C) Standard mortar/pestle. 
 
Figure 2: Viscosity analysis of the binary mixtures containing various ratios of ORA-Plus® (O) 
and water (W). 
 
Figure 3: Viscosity analysis of eslicarbazepine acetate suspension (40 mg/mL and 60 mg/mL) 
prepared using ORA-Plus®: water (50:50, v/v) as a suspending vehicle. 
 
Figure 4: Viscosity analysis of eslicarbazepine acetate suspension (40 mg/mL) in various ratios 
of ORA-Plus® (O) and water (W). 
 
Figure 5: Physical stability (0- 48 hours) of eslicarbazepine acetate suspension (40 mg/mL) in 
various ratios of ORA-Plus® (O) and water (W). 
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Table 1: Forced-degradation study parameters 
Sample Forced Degradation Treatment 
1 Adjusted to pH 2 using 1 N HCl and incubated at 60°C  
2 Adjusted to pH 12 using 1 N NaOH and incubated at 60°C  
3 Spiked with 3% hydrogen peroxide and incubated at 60°C  
4 
Spiked with 3% hydrogen peroxide and exposed to direct 
sunlight (ambient room temperature)  
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Table 2: Mean particle size of powders obtained from different tablet crushing methods  
Sample Mean size (μm) Std. Dev. (μm) 
Pillcrusher Syringe 389.6  149.5 
Silent Knight® pill crusher 412.5 81.6 
Standard mortar/pestle 68.2 2.4 
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Table 3. Mean concentration (%) of eslicarbazepine in the prepared suspensions (40 mg/mL).  
Trial 
Eslicarbazepine concentration (mean, %) 
Sample 1 Sample 2 Sample 3 Average 
1 95.9 98.9 98.7 98 ± 0.02 
2 101.7 101.1 99.1 101 ± 0.01 
(n=3) 
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Table 4. Mean concentration (%) of eslicarbazepine in the prepared suspension (40 g/mL) after passing 
through enteric feeding tubes. 
Tube Type 
Eslicarbazepine concentration (mean, %) 
Sample 1 Sample 2 Sample 3 Average 
PVC, 18 Fr, 48" 101.5 103.6 102.6 102.6 ± 1.1 
PVC, 10 Fr, 36" 101.7 104.3 100.8 102.3 ± 1.8 
Polyurethane, 10 Fr, 36" 102.5 103.3 103.9 103.2 ± 0.7 
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Table 5. Mean concentration (%) of eslicarbazepine in the prepared suspension (40 mg/mL) following 24 
and 48 hour storage at room temperature.  
Time 
Eslicarbazepine concentration (mean, %) 
Sample 1 Sample 2 Sample 3 Average 
0 hour 104.0 102.0 104.0 103.3 ± 1.2 
24 hours 103.0 97.0 104.0 101.3 ± 3.8 
48 hours 103.0 102.0 105.0 103.3 ± 1.5 
 
 
 
 
